Back to TVTX
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Focal Segmental Glomerulosclerosis
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/19/2024
Filspari
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts